Background: Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas. Methods: Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome. The current study extrapolates this conventional wisdom and combines it with molecular profiling. We developed an 18-gene signature that molecularly defines urothelial cellular differentiation, thus classifying MIBCs and NMIBCs into two subgroups: basal and differentiated. We evaluated the prognostic capability of this "tumor differentiation signature" and three other existing gene signatures including the The Cancer Genome Atlas (TCGA; 2707 genes), MD Anderson Cancer Center (MDA; 2252 genes/2697 probes), and University of North Carolina at Chapel Hill (UNC; 47 genes) using five gene expression data sets derived from MIBC and NMIBC patients. All statistical tests were two-sided. Results: The tumor differentiation signature demonstrated consistency and statistical robustness toward stratifying MIBC patients into different overall survival outcomes (TCGA cohort 1, P ¼ .03; MDA discovery, P ¼ .009; MDA validation, P ¼ .01), while the other signatures were not as consistent. In addition, we analyzed the progression (Ta/T1 progressing to T2) probability of NMIBCs. NMIBC patients with a basal tumor differentiation signature associated with worse progression outcome (P ¼ .008). Gene functional term enrichment and gene set enrichment analyses revealed that genes involved in the biologic process of immune response and inflammatory response are among the most elevated within basal bladder cancers, implicating them as candidates for immune checkpoint therapies. Conclusions: These results provide definitive evidence that a biology-prioritizing clustering methodology generates meaningful insights into patient stratification and reveals targetable molecular pathways to impact future therapeutic approach.
subclassification of bladder cancer into distinct subtypes based on unique molecular signatures (8) (9) (10) (11) (12) (13) . We previously reported a basal subtype of MIBCs characterized by high expression of cytokeratins (KRT14/KRT5) and cell surface receptors (Thy-1/CD44) that are generally expressed in stem and basal cells of the normal bladder urothelium (6, 7) . Independently, TCGA reported four clusters of MIBCs with various characteristics (9) . Cluster I/II tumors resembled papillary histology, and Cluster III/IV tumors expressed high levels of cytokeratins (KRT14/KRT5), along with other surface proteins reported to mark stem/basal cells (9) . Additional studies from Lund University, the MD Anderson Cancer Center (MDA), and the University of North Carolina at Chapel Hill (UNC) reported MIBCs with basal and luminal characteristics (8, 10, 11) . Despite the independent clustering methodologies employed, there are overlaps between the different subclassifications proposed. A consensus meeting held in 2015 concluded that MIBCs can be classified into at least two major subtypes: basal/squamous-like (BASQ) and differentiated/luminal (14) . State-of-the-art clinical trials now evaluate whether cancer subtyping plays a role in understanding therapeutic responses (15) (16) (17) (18) . While subclassification of MIBCs into subtypes reveals an exciting area of research, we rationalized that a methodology that assimilates biology during data analysis may provide valuable insights. Clinically, tumor grading is a pathological evaluation of tumor differentiation that often associates with patient outcome. The current study extrapolates this conventional wisdom into molecular profiling by developing a biology-based clustering methodology from a panel of 18 genes that define various stages of urothelial cell differentiation (7) . The prognostic value of this newly defined "tumor differentiation signature" was compared with other published signatures in stratifying clinical outcome. The overarching goal is to demonstrate the relevance to consider tumor biology during classification of tumors into subtypes.
Methods

Statistical Methods for Clustering and Classification Analysis of the Bladder Cancer Data Sets
We evaluated the prognostic capability of four classifiers, including TCGA (2707 genes), MDA (2252 genes/2697 probes), UNC (47 genes), and the tumor differentiation (18 genes) signatures using five gene expression data sets derived from human MIBC and NMIBC patients ( Table 1) . The TCGA MIBC data were generated by RNA-seq, and gene expression was quantified by the RSEM method and normalized within sample to a fixed upper quartile (9) . The other four data sets were generated by Illumina microarrays, and the normalized data were directly downloaded from the GEO website (http://www.ncbi.nlm.nih.gov/geo/). For microarray data sets, when there were multiple probes for a gene, we chose the one with largest variance to represent the gene. To make the data sets comparable, for each gene in each data set, we standardized its expression values by subtracting the sample mean and then dividing by the sample standard deviation. We used the TCGA data set and hierarchical clustering algorithm (with 1 -Pearson correlation coefficient as the distance between samples and the "complete" agglomeration method) to generate the expression signature for the 18-gene tumor differentiation classifier in which the patient samples were clustered into two subgroups with distinct expression patterns. Using the clustered TCGA data set as the training data set and Euclidean distance based on the 18 genes as the metric to define the neighborhood among samples, we then classified the samples in the other three data sets into the two subgroups using the 1-nearest neighbor algorithm. For the other three gene signatures, if the samples in each data set had been classified, we directly used the results for comparison (ie, MDA discovery data sets). Otherwise, the 1-nearest neighbor algorithm was used for the classification analyses.
Survival and Functional Enrichment Analyses
Kaplan-Meier method was used to generate survival curves for the subgroups in each data set, and the log-rank test was used to test if they were statistically different. Moderated t-statistics were used to test if genes were differentially expressed between the groups of interest, and the Benjamini-Hochberg method was used to estimate false discovery rate (FDR) (19) . Genes with an FDR of less than 0.05 were considered statistically significant. Gene functional term enrichment analysis was performed using the DAVID bioinformatics tools (https://david.ncifcrf.gov/) for the differentially expressed genes. Gene set enrichment analysis was performed using GSEA software (http://software. broadinstitute.org/gsea/index.jsp). All the statistical analyses were performed using R (https://www.r-project.org/), and the P values were two-sided. P values of less than .05 were considered statistically significant.
Results
Compiling a Biology-Based Tumor Differentiation Gene Signature
Tumor grade is defined by pathologic evaluation of tumor cell differentiation, which historically associates with disparate biologic behaviors (7) . While all MIBCs are pathologically evaluated as high-grade cancers (T2 and higher), we hypothesized that expression of genes associated with urothelial cell differentiation (within a tumor) might provide molecular information to its corresponding differentiation status. Thus, such molecular information likely complements pathologic grading and reflects pathobiology that might better predict outcome (6, 7) . First, we developed a classifier from 18 genes differentially expressed in various layers of the bladder urothelium (ie, different cellular differentiation stages) (Figure 2A ). Established cytokeratins, uroplakins, and clusters of differentiation (CD) markers were selected on the basis of their expression corresponding to various differentiation stages or cell layers of the bladder urothelium ( Figure 2A ). For instance, KRT5/17 and CD44 are reported to be expressed in basal cells of human urothelium (7, 21, 22) . KRT14, originally thought to define urothelial squamous differentiation (21, 23) , was also reported to be expressed in early stem/progenitor cells in the urothelial basal layer (6) . A recent study employing a KRT14 Cre reporter mouse followed by lineage-tracing in bladder urothelium provided definitive evidence demonstrating that KRT14 could mark stem/progenitor cells, with the capacity of giving rise to all urothelial layers (24) . Cytokeratins 8/18 are expressed in the intermediate and more differentiated urothelial cells, while cytokeratin 20 and uroplakins are expressed in terminally differentiated umbrella cells that are adjacent to the lumen (Figure 2A ) (25, 26) . We previously reported that constitutive expression of Stat3 drives invasive progression of MIBCs in a mouse model (27) . STAT3 is known to maintain stem cell self-renewal (28) , and its expression closely associates with basal KRT14 expression (27) . Therefore, STAT3 and its upstream regulators, including EGFR and JAK2, were also included in the tumor differentiation signature (12) .
Subclassification of Human MIBCs Into Basal and Differentiated Subtypes
We employed this 18-gene tumor differentiation signature to stratify the published TCGA cohort of 129 MIBC patients with RNA sequencing data (9) and identified two distinct subtypes ( Figure 2B ). The first MIBC subtype expressed a higher level of 
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basal cytokeratins and other genes associated with urothelial basal cells, while expression of differentiation genes was relatively lower, and was therefore designated as "basal" subtype. The second MIBC subtype expressed a relatively lower level of basal genes and higher level of differentiation genes, and was therefore designated as "differentiated" subtype. Several molecular classification studies on human MIBCs have been published in the recent years. For instance, a published TCGA study performed unsupervised clustering analysis of 129 MIBC patient samples using 2707 genes, which stratified patients into four "clusters" (Clusters I, II, III, and IV) ( Figure 2C ). The MDA group performed unsupervised clustering analysis of 73 primary fresh-frozen MIBC specimens using 2252 genes (2697 probes) that generated three subtypes including basal, p53-like, and luminal (10) . The UNC group performed consensus clustering analysis of a meta-data set that identified basal and luminal subtypes and further identified 47 genes as the subtype predictor (11) . Using the 18-gene tumor differentiation signature and the other three existing gene signatures (TCGA/MDA/UNC), we classified patient specimens in the testing data sets into corresponding subtypes using the 1-nearest neighbor method with Euclidean distance. The MDA gene signature and the UNC gene signature presented by the TCGA data set are shown in Figure 2 , D and E, respectively, where patient specimens were classified using the 1-nearest neighbor method and genes were arranged by hierarchical clustering using 1 -Pearson correlation coefficient as distance and complete agglomeration algorithm. The heatmap representation of these four gene signatures presented by different published data sets is shown in Supplementary Figure 1A (available online).
Prognostic Value of Tumor Differentiation Signature in Stratifying Patient Survival in Comparison With Other Existing Gene Signatures
Next, we investigated whether the basal and differentiated subtypes defined by the tumor differentiation signature using the published TCGA cohort (9) had prognostic value. The basal MIBC subtype had worse overall survival compared with the differentiated subtype (P ¼ .03) ( Figure 3A) . Similarly, the UNC basal subtype also had worse overall survival compared with the luminal subtype (P ¼ .04) ( Figure 3J ). In contrast, in terms of overall survival, the TCGA subtypes were not statistically significantly different (P ¼ .19) ( Figure 3D ), and the MDA subtypes were marginally statistically significantly different (P ¼ .09) ( Figure 3G ).
We further evaluated the prognostic value of the tumor differentiation signature in additional MIBC cohorts (Table 1) . The tumor differentiation signature reproducibly stratifies overall survival in these cohorts, with the basal subtype associated with a statistically significantly worse overall survival (P ¼ .009, P ¼ .01, P ¼ .001) ( 
Comparison of MIBC Subtype Assignments by Different Gene Signatures
While in reviewed literature, basal and luminal (or differentiated) subtypes of MIBCs stratified by different signatures correspond well (29) ; raw data supporting such claims have not been available, and therefore warrant careful evaluation. Figure 4 summarizes the relative cancer subtype assignments by each of the four gene signatures evaluated in the current study and illustrates how they relate to their counterparts in other studies. For every subtype or cluster, we determined the proportion of specimens that would be stratified as basal or differentiated subtypes based on the tumor differentiation signature. These data demonstrate that the TCGA cluster III and IV tumors correspond well with the basal cancer subtypes classified by MDA, UNC, and the tumor differentiation signature ( Figure 4A ; Supplementary Figures 2B and 4B , available online). In the TCGA and MDA discovery cohorts, we found that most of the Cluster III and IV tumors had a gene signature that was considered basal ( Figure 4D ; Supplementary Figures 2C and 4C , available online).
Within the MDA discovery and validation cohorts, the tumor differentiation signature classified specimens to basal or differentiated, which highly overlap with the basal and luminal subtypes assigned by the MDA group, respectively; however, the "p53-like tumors" were divided between basal and differentiated subtypes (Figure 4 , A-C). While earlier reports suggested that p53-like tumors were mainly luminal, these findings further corroborate recent studies recognizing that the "p53-like" subtype is composed of both luminal and basal tumors (30) . More than 50.0% of the "p53-like tumors" were classified as basal tumors by the UNC signature within the MDA validation cohort ( Figure 4C) ; 73.2% of the TCGA Cluster I tumors and 83.3% of the TCGA Cluster II tumors had a gene signature that was considered "differentiated" by the tumor differentiation signature ( Figure 4, A and D; Supplementary Figures 2, B and C, and 4 , B and C, available online). These results are insightful in laying out the variability among subtype assignments by different signatures in different patient cohorts.
Tumor Differentiation Signature as a Predictor of PFS in NMIBC
NMIBCs have a favorable prognosis. However, 15.0% to 20.0% of NMIBCs eventually progress to aggressive MIBCs (20, 31) . Predicting NMIBC progression and the underlying molecular pathways involved has been an overarching goal. Here, we examined the power of the tumor differentiation signature to predict disease progression in NMIBC patients using a published data set of 460 NMIBC patients (20) . The tumor differentiation gene signature stratified patients into basal and differentiated groups ( Figure 5A) , with 83.3% (383/460) of NMIBC patients clustered into the differentiated group. The basal tumors were strongly associated with worse progression-free survival (P ¼ .008) ( Figure 5B ) and progression to T2 stage ( basal: 12.9%, 95% CI ¼ 7.1% to 22.1%; vs differentiated: 5.1%, 95% CI ¼ 3.1% to 7.9%; P ¼ .009) ( Figure 5C ). The distributions of the NMIBC patients who progressed to T2 (20) in the basal and differential subtypes are shown in Figure 5D . Collectively, these results indicate that the tumor differentiation status of NMIBCs is one determining factor that influences tumor progression, but clearly not the sole factor.
Pathways Associated With Basal and Differentiated Subtypes Defined by the Tumor Differentiation Signature
As the basal and differentiated MIBC subtypes were associated with overall survival, we further investigated the molecular pathways associated with each subtype. Gene functional term enrichment analysis of upregulated genes revealed many overlaps of the top 10 pathways enriched in the basal subtype of MIBCs and NMIBCs ( Figure 6 , A-E). These results indicate that common pathways, such as those related to epidermis development, cell adhesion, and inflammatory, immune, and defense responses, are activated in the basal subtype. Gene set enrichment analysis (GSEA) identified members of cytokines and the cytokine receptor family, as well as toll-like receptors (TLRs) and the chemokine (CXCL) family, as elevated in basal MIBCs ( Figure 6F , Table 2 ), indicating an inflammatory and immuneinfiltrating microenvironment (32) . This is further supported by co-expression of genes corresponding to various T-cell subsets, as well as a master regulator of cancer inflammation-STAT3 ( Figure 6G ) (33) . While further analysis and functional experiments are needed to determine the pro-or antitumoral roles of these immune infiltrates, we found that basal MIBCs also highly expressed genes encoding cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed death-ligand 1 (PD-L1 or CD274) with established roles in immunosuppression, as well as other genes with immune regulatory roles ( THY1  STAT3  JAK2  KRT15  EGFR  ITGA6  KRT14  KRT5  KRT17  CD44  UPK1B  UPK1A  UPK3A  UPK2  UPK3B  KRT20  KRT18 metabolism, and peroxisome proliferator activated receptor gamma (PPARG) pathways (Table 2) . Drug-induced activation of PPARG has been previously reported to promote cellular differentiation in normal human urothelial cells, demonstrated by upregulation of differentiation markers such as UPKs and KRT20 (7, 37, 38) . Such a phenotype is reminiscent of the differentiated subtype of MIBCs, which express high levels of differentiated genes, for example, UPKs and KRT20 ( Figure 2B ).
Discussion
Molecular classification of human epithelial cancers (eg, breast cancer) into distinct molecular subtypes has opened an avenue to personalized medicine, for example, herceptin for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients (39) . Such clinical advances brought enthusiasm to genomic profiling of other cancer types. Until recently, bladder urothelial carcinomas lagged behind in terms of molecular subtyping. TCGA and multiple groups have published molecular signatures that classify bladder cancers into distinct subgroups (8) (9) (10) (11) (12) (13) . Each of these signatures has their own validity, as they were either geared toward a specific clinical outcome or utilized a conventional unsupervised hierarchical clustering strategy without necessarily considering cancer biology during data analysis. Our study is unique in that it shows that differentiation state can be used to classify MIBC tumors into biologically meaningful subtypes: namely "basal" and "differentiated" subtypes. When applied to multiple published data sets, this biology-based gene signature is highly consistent in stratifying patient overall survival. An important goal of subtyping is the identification of molecular pathways deregulated within each cancer subtype, which provides opportunities for precision medicine. Our pathway analysis of basal and differentiated tumor subtypes revealed FDA-approved drug targets for basal MIBCs (eg, CTLA-4 and PD-L1), as well as master transcriptional regulators of cellular differentiation that associate with each subtype (eg, Stat3 for basal subtype and PPARG for differentiated subtype), supporting our conception that bladder cancer is a disease of aberrant cellular differentiation (7) . In fact, a mouse model overexpressing active Stat3 in urothelial basal cells demonstrated features of human basal bladder cancers (27) .
While anti-CTLA4 and anti-PD-L1 immunotherapies are highly effective in certain patient subpopulations, a major clinical challenge is the lack of predictive markers available to Recently, another meticulous study performed an integrated analysis across 12 cancer types and found that certain cancer subtypes are closely related to their tissue of origin (41) . In their objective and comparative analysis, bladder cancer was found to be one of the most diverse cancer types, with specimens clustered into seven out of 11 major subtypes (41) . Here, by employing a biology-based clustering method, we could define such a molecularly diverse cancer type (41) into two biologically distinct subtypes that statistically associated with clinical prognosis. Importantly, this tumor differentiation gene signature outperforms the TCGA signature in predicting patient survival. This concept is further supported by recent studies in other cancer types, for example, acute myeloid leukemia (42) and prostate cancer (43) , where stem cell genes were successfully used to stratify patients into groups with differential survival outcome (42) or to identify patients associated with pathologically aggressive cancers (43), respectively. With further identification and characterization of study models that recapitulate the bladder cancer subtypes (as in [44] [45] [46] ), preclinical studies can be designed to reveal valid drug targets (47, 48) , which can impact patient care for bladder urothelial carcinomas.
Our study has its limitations. We utilized published data sets, which renders our study design retrospective. Therefore, it is essential to validate our findings in prospective studies of treatment-naïve MIBC patients. Another limitation is that the analysis is primarily based on treatment-naïve MIBC patient cohorts. Classification of patient cohorts treated with different regimens (eg, chemotherapy or immunotherapy) using the tumor differentiation signature will provide important information for understanding its usefulness in selecting patients that might benefit from the given therapies. QM and FC are supported in part by the National Cancer Institute Center Core Grants 5P30CA125123 (to CKO). KSC is supported in part by the V Scholar Award. KH is supported in part by NIH T32GM088129, and JJS is supported in part by CPRIT Core Facility Support Awards RP120348 and RP170002.
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